Vesugen: what it is and what the evidence says
A tripeptide from the same school, proposed for the vascular endothelium.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Two very different things live under the same label here: serious research into mitochondria, cellular senescence and DNA repair, and a market of promises built on studies that were never replicated. Telling them apart is most of the work, and this is the area where it matters most to look at who signed each study.
What it is studied for
Advertised for vascular health.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There is one open-label study published in Russian (Adv Gerontol, 2015) in 32 people aged 41 to 83 with chronic multimorbidity who received Vesugen or Pinealon; it reports a slower rate of aging on biological age indicators, more marked with Vesugen. The tripeptide's patent also describes observations in people with capillary fragility.
The limitation that matters most
Still missing are placebo-controlled trials, measurements of vascular function in people such as flow-mediated dilation, pharmacokinetic data, and replication by laboratories unrelated to the originating institute. The remaining support is cell culture work and mouse studies.
Regulatory status
Not approved as a medicine by the FDA or the EMA. In Russia it is registered as a dietary supplement in capsules and as a sublingual solution. It is not listed by name on the 2026 WADA Prohibited List, although category S0 covers substances with no approval as a medicine; anyone who competes under anti-doping rules should confirm its status with their federation.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It is the bioregulator with the least literature of all: barely half a dozen papers, almost all in vitro.
With high blood pressure, diabetes, cardiovascular disease, anticoagulants, pregnancy, or active cancer, have your doctor assess it before you start, and keep your prescribed treatment in place.
What this page cannot give you
A reference page can take you this far. You know what Vesugen is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]human Adv Gerontol · 2015 · PMID 26390612 →
- [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]preclinical Adv Gerontol · 2014 · PMID 25051766 →
- Peptides tissue-specifically stimulate cell differentiation during their agingpreclinical Bull Exp Biol Med · 2012 · PMID 22808515 →
- [Biological activity of regulatory peptides in model experiments in vitro]preclinical Adv Gerontol · 2008 · PMID 18546826 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Vesugen or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Vesugen?
A tripeptide from the same school, proposed for the vascular endothelium. It is studied within the area of longevity/cellular.
Is there human evidence for Vesugen?
There is one open-label study published in Russian (Adv Gerontol, 2015) in 32 people aged 41 to 83 with chronic multimorbidity who received Vesugen or Pinealon; it reports a slower rate of aging on biological age indicators, more marked with Vesugen. The tripeptide's patent also describes observations in people with capillary fragility.
Is it approved by any health agency?
Not approved as a medicine by the FDA or the EMA. In Russia it is registered as a dietary supplement in capsules and as a sublingual solution. It is not listed by name on the 2026 WADA Prohibited List, although category S0 covers substances with no approval as a medicine; anyone who competes under anti-doping rules should confirm its status with their federation.
What is the dose of Vesugen?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Vesugen is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.